For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

Creating and bringing new medicines to patients is a uniquely complicated process. It requires robust scientific research, business acumen, tremendous financial investment, and patience — even when ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a ...

Essential medicines play a vital role in America’s health, and the supply is closely monitored by the FDA and industry groups. These medicines sustain life, provide life support and/or the prevention ...

Life sciences leaders are awaiting outcomes of the Section 232 investigation concerning the national security implications of importing pharmaceuticals and related ingredients, which include finished ...

At some point in their career, nearly everyone believes that leadership is about guiding every situation with complete balance and control. It’s natural to think that strength comes from always having ...